Topics

CNS Tumors | Treatment | Targeted therapy | Nivolumab

Home > Publications > Topics > CNS Tumors > Treatment > Targeted therapy > Nivolumab

André N, Deley MCL, Léguillette C, Probst A, Willems L, Travers R, Aerts I, Faure-Conter C, Revond-Riviere G, Min V, Geoerger B, Chastagner P, Entz-Werlé N, Leblond P.
METRO-PD1: Phase 1 study of nivolumab in combination with metronomic chemotherapy in children and adolescents with relapsing/refractory solid tumors.
Eur J Cancer. 2024 Jan 6;198:113525. doi: 10.1016/j.ejca.2024.113525. PMID: 38199147. Interventional study. ˍ

Astrocytoma, anaplastic; Astrocytoma, NOS; Glioblastoma, NOS; Oligodendroglioma, anaplastic; Oligodendroglioma, NOS

Nguyen MK, Jelinek M, Singh A, Isett B, Myers ES, Mullett SJ, Eisele Y, Beumer J, Parise R, Urban J, Rose A, Sellitto L, Singh K, Doerfler R, Dadey RE, Kim C, Rhee JC, Davar D, Villaruz LC, Burgess M, Drappatz J, Mantica M, Goodman AE, Wang H, Singhi AD, Luke JJ, Zandberg DP, Bao R.
Clinical and translational study of ivosidenib plus nivolumab in advanced solid tumors harboring IDH1 mutations.
medRxiv [Preprint]. 2025 Jul 21:2025.07.19.25331848. doi: 10.1101/2025.07.19.25331848. PMID: 40778139. Interventional study. ˍ ClinicalTrials.gov ID: NCT04056910.